Fiducient Advisors LLC bought a new position in Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 738 shares of the company’s stock, valued at approximately $430,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Parthenon LLC raised its position in Eli Lilly and Company by 1.7% in the 4th quarter. Parthenon LLC now owns 5,765 shares of the company’s stock worth $3,361,000 after purchasing an additional 98 shares during the period. MONECO Advisors LLC grew its position in Eli Lilly and Company by 8.9% in the 4th quarter. MONECO Advisors LLC now owns 3,023 shares of the company’s stock valued at $1,762,000 after acquiring an additional 247 shares during the last quarter. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 6.3% during the fourth quarter. Brighton Jones LLC now owns 9,674 shares of the company’s stock worth $5,639,000 after purchasing an additional 577 shares during the last quarter. Vanguard Capital Wealth Advisors grew its holdings in shares of Eli Lilly and Company by 10.1% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 545 shares of the company’s stock worth $318,000 after purchasing an additional 50 shares during the last quarter. Finally, Mission Wealth Management LP raised its stake in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Mission Wealth Management LP now owns 7,213 shares of the company’s stock valued at $4,204,000 after acquiring an additional 26 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Price Performance
Shares of NYSE:LLY traded down $5.26 during midday trading on Wednesday, hitting $775.84. The company’s stock had a trading volume of 689,474 shares, compared to its average volume of 3,041,018. The company has a market cap of $737.17 billion, a P/E ratio of 133.85, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. Eli Lilly and Company has a 12-month low of $399.26 and a 12-month high of $800.78. The business’s 50 day simple moving average is $761.41 and its 200 day simple moving average is $669.21. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.
Analysts Set New Price Targets
LLY has been the subject of a number of analyst reports. Bank of America upped their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Citigroup increased their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Morgan Stanley boosted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $733.65.
Check Out Our Latest Research Report on LLY
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Stocks to Consider Buying in October
- Amazon Stands Tall: New Highs Are in Sight
- The 3 Best Retail Stocks to Shop for in August
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.